In this study, endogenous long chain ceramides were measured in 32 human head and neck squamous cell carcinoma (HNSCC) and 10 nonsquamous head and neck carcinoma tumor tissues, as compared with adjacent noncancerous tissues, by liquid chromatography/ mass spectroscopy. Interestingly, only one specific ceramide, C 18:0 -ceramide, was selectively down-regulated in the majority of HNSCC tumor tissues. On the other hand, in nonsquamous tumor tissues, this selectivity for C 18 -ceramide was not detected. These data suggested the hypotheses that decreased levels of C 18 -ceramide might impart a growth advantage to HNSCC cells and that increased generation of C 18 -ceramide may be involved in the inhibition of growth. These roles were examined by reconstitution of C 18 -ceramide at physiologically relevant concentrations in UM-SCC-22A cells (squamous cell carcinoma of hypopharynx) via overexpression of mammalian upstream regulator of growth and differentiation factor 1 (mUOG1), a mouse homologue of longevity assurance gene 1 (mLAG1), which has been shown to specifically induce the generation of C 18 -ceramide. Liquid chromatography/mass spectroscopy analysis showed that overexpression of the mLAG1/ mUOG1 resulted in increased levels of only C 18:0 -ceramide by ϳ2-fold, i.e. concentrations similar to those of normal head and neck tissues. Importantly, increased generation of C 18 -ceramide by mLAG1/mUOG1 inhibited cell growth (ϳ70 -80%), which mechanistically involved the modulation of telomerase activity and induction of apoptotic cell death by mitochondrial dysfunction. In conclusion, this study demonstrates, for the first time, a biological role for LAG1 and C 18 -ceramide in the regulation of growth of HNSCC.
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one of the six most common cancers in the world, is associated with poor survival and high mortality rates. Global occurrence rate of HNSCC is estimated to be ϳ5% of the total malignancies in the adult population, and in the United States there are ϳ40,000 annual cases of HNSCC (1) (2) (3) . Despite advances in treatment, including surgery, radiation, and chemotherapy, survival statistics of patients with this disease have not improved significantly in decades (3, 4) . Although p53, cyclin D1, K-Ras, Rb, and telomerase have been identified as prognostic markers for HNSCC (5) , delineation of pathogenic mechanisms is required for understanding the biology of these tumors, for designing optimized therapy, and for identification of specific diagnostic and prognostic markers.
The bioactive sphingolipid ceramide, an emerging tumor suppressor lipid, mediates anti-proliferative responses such as apoptosis, cell cycle arrest, and senescence (6, 7) . Our recent studies have shown that ceramide is one of the upstream regulators of telomerase activity (8 -10) and that the regulation of telomerase by ceramide involves the inactivation of c-Myc transcription factor via increased ubiquitin/proteasome function for its rapid proteolysis (11) . It is well established that telomerase is active in ϳ80 -90% of the tumor tissues of the HNSCCs, whereas it is not active in normal head and neck tissues (12) (13) (14) (15) . These results suggested to us that endogenous levels of ceramide may also be misregulated in HNSCC.
Endogenous ceramide levels can be altered by various mechanisms, including de novo synthesis of ceramide or activation of sphingomyelinases, which can regulate cell growth (16) . One of the key enzymes of the de novo pathway is (dihydro)ceramide synthase, and in Saccharomyces cerevisiae longevity assurance gene 1 (LAG1) and its homologue Lac1 were identified as components of ceramide synthase activity (17, 18) . Recent studies have shown that one of the mouse homologues of LAG1, known as upstream of growth and differentiation factor 1 (mUOG1 or mLAG1) selectively regulates the synthesis of stearoyl (C 18 )-containing sphingolipids, including C 18 -ceramide (19) . The human homologue of the mLAG1/mUOG1 (hLAG1, LAG1Hs, or LASS1) has recently been identified and has Ͼ80% amino acid homology with mLAG1 (20, 21) . Subsequently, two additional homo-logues of mammalian LAG1 family members, trh1 and trh4, were identified to regulate ceramide synthesis using different fatty acyl CoA donors (22) . Overexpression of trh1 increased mainly stearic acid and arachidic acid-containing sphingolipids, and trh4 overexpression elevated mainly palmitic acidcontaining sphingolipids (22) .
Because the clinical relevance of endogenous ceramide and its roles in the regulation of cell growth in HNSCC has not been established previously, this study first focused on examining the levels of endogenous ceramide in clinical samples obtained from patients with HNSCC. Unexpectedly, the data demonstrated that only C 18 -ceramide is down-regulated significantly in the majority of the HNSCC when compared with their adjacent normal tissues. However, in nonsquamous tumors, this selective down-regulation of C 18 -ceramide was not detected, suggesting a specific role for C 18 -ceramide in the pathogenesis/ progression of HNSCC. Further evidence is presented to establish the role of LAG1/C 18 -ceramide in the inhibition of growth, modulation of telomerase activity, and induction of apoptosis in HNSCC cells in vitro. To our knowledge, this is the first study demonstrating a biological role for LAG1 and C 18 -ceramide in the regulation of growth of HNSCC.
EXPERIMENTAL PROCEDURES
Tissue Samples and Statistical Analysis-Tumors and their paired adjacent noncancerous tissues of HNSCC and nonsquamous head and neck cancer patients were obtained from the Tumor Bank at the Hollings Cancer Center (Medical University of South Carolina) with the permission of the Institutional Review Board. Normal adjacent tissues, which were mucosal tissues that were not grossly or histologically cancerous or precancerous, were excised at least 1 cm away from the main tumor mass of the patients. Some of the patients (HNSCC patients 1-17) have tissues from their tumor mass and from their normal adjacent part, which were referred as "paired" samples, and some patients (HNSCC patients 18 -32) have only their tumor tissues without normal adjacent tissues. The type of disease and the levels of FIG. 1. Analysis of ceramide levels in tumor versus normal tissues of patients with HNSCC. Levels of ceramide in tumors and their paired adjacent normal tissues obtained from patients with HNSCC were measured by LC/MS as described under "Experimental Procedures." First, total ceramide levels (A) and ceramide species (B) in 17 paired samples of HNSCC tissues were analyzed. The total levels of only C 18 -ceramide was lower in tumor as compared with normal tissues (B). The error bars represent the standard deviations, and when not seen, they are smaller than the thickness of the lines on the graphs. Tables I and II . Ceramide measurements in these samples were performed by LC/MS as described below. Statistical analyses of the results were performed using Student's t test.
Measurement of Ceramide Levels Using High Performance LC/MSThe cellular levels of endogenous ceramides were measured using normal phase high performance liquid chromatography coupled to atmospheric pressure chemical ionization-mass spectrometry (LC/MS) as described previously (9) . The ceramide levels were normalized to total protein levels (0.5 mg of protein/sample).
Cell Lines and Culture Conditions-Human head and neck cancer cell lines UM-SCC-1 (SCC of retromolar trigone/floor of the mouth) and UM-SCC-22A (SCC of hypopharynx) cells (23) were obtained from Dr. Thomas Carey at the Department of Otolaryngology/Head and Neck Surgery, University of Michigan. The cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 1% penicillin/streptomycin at 37°C in 5% CO 2 .
Detection of Growth Inhibition by MTT and Trypan Blue AssaysThe concentrations of agents that inhibited cell growth by 50% (IC 50 ) were determined from cell survival plots obtained by MTT or trypan blue assays as described (8) . Triplicate wells were used for each treatment.
Plasmids and Transfections-The complete cDNA (1.4 kb) for mammalian UOG1 (mLAG1/mUOG1) was cloned in the pCMVexSVneo plasmid and used for transfections of UM-SCC-22A and UM-SCC-1 cells using an Effectine transfection kit (Qiagen) as described previously (8) .
Quantitative Real Time (Q)-PCR and Conventional Semi-quantitative Reverse Transcription (RT)-PCR-One g of total RNA, isolated using an RNA isolation kit (Qiagen), was used in reverse transcription reactions as described (8) . The resulting total cDNA was then used in the Q-PCR or RT-PCR as described previously (8, 16) . The mRNA levels of ␤-actin and rRNA were used as internal controls.
Measurement of Telomerase Activity-Telomerase activity in cell extracts was measured by the PCR-based telomere repeat amplification protocol (TRAP) using TRAPeze kit (Intergen, Gaithersburg, MD) which includes a 36-bp internal control to allow quantification of activity as described (8 -10) .
Analysis of Mitochondrial Membrane Potential-The collapse of an electrochemical gradient across the mitochondrial membrane during apoptosis was measured using a JC-1 mitochondrial membrane potential detection kit (Cell Technology) by flow cytometry as described by the manufacturer. This kit uses a unique cationic dye, JC-1, to signal the loss of the mitochondrial membrane potential. In healthy cells, the dye accumulates in the mitochondria as aggregates, which become fluorescent red. In apoptotic cells, the mitochondrial potential collapses, and the JC-1 cannot accumulate within the mitochondria and remains in the cytoplasm as a green fluorescent monomeric form. These different forms of JC-1 were then detected by flow cytometry as described by the manufacturer.
RESULTS

Analysis of Ceramide Levels in HNSCC Tumor
Tissues-The levels of endogenous ceramides in 17 pairs of HNSCC and 10 pairs of nonsquamous head and neck tumor tissues were measured and compared with their paired adjacent noncancerous tissues using LC/MS as described. Unexpectedly, as shown in Fig 1A, the results showed that the total ceramide levels were higher in the HNSCC tumor tissues as compared with their noncancerous tissues (2393 and 1505 pmol/0.5 mg protein, respectively). However, when individual ceramide species were examined in these paired samples (n ϭ 17), the results demonstrated that only C 18:0 -ceramide was ϳ50% lower in HNSCC tumor tissues as compared with their noncancerous counterparts (103 versus 196 pmol/0.5 mg protein), whereas the levels of all the other ceramides were generally higher in HNSCC tumors than their controls (Fig. 1B) . When the levels of C 18:0 -ceramide were further evaluated in each patient sample, the results showed that 12 of 17 patients (70% of the patients, p Ͻ 0.01) had significantly lower levels of C 18:0 -ceramide in their tumor tissues compared with their adjacent noncancerous tissues ( Fig. 2A and Table I , patients 1-17). 
LAG1 and C 18 -ceramide in the Regulation of Growth of HNSCC
To investigate whether decreased levels of C 18 -ceramide are due to altered expression of hLAG1, a human homologue of mLAG1/mUOG1 that has been shown to specifically increase C 18 -ceramide generation, total RNA was isolated initially from normal and HNSCC tumor tissues of the patient 6, and then mRNA levels of hLAG1 were examined by RT-PCR and Q-PCR (Fig. 2, B and C, respectively) . The results showed that hLAG1 mRNA expression was significantly decreased in the tumor as compared with its adjacent normal tissue (Fig. 2, B, lanes 3 and 2, respectively, and C), and this correlated with the decreased levels of C 18 -ceramide in the tumor tissue of this patient ( Fig.  2A) . However, mRNA levels of hLAG1 were similar in both the normal and tumor tissues of patient 9 (Fig. 2D ), whose C 18 -ceramide levels were also comparable in these tissues. These data indicate that C 18 -ceramide levels might be regulated by the expression of LAG1 at the mRNA level in HNSCC; however, this needs to be determined in a larger cohort of patient samples, when they are available.
The levels of C 18:0 -ceramide in noncancerous tissues obtained from patients with HNSCC were similar (ϳ11.5 pmol/ 500 g protein/sample with a standard deviation of Ϯ4). Therefore, the average level of C 18:0 -ceramide of these noncancerous tissues was used in the examination of ceramide levels in 15 additional HNSCC tumor tissues for whom matched noncancerous tissues were not available (Fig. 3A and Table I, patients 18 -32). The results of the LC/MS analysis showed that 7 of 15 tumor tissues exhibited significantly lower levels of C 18:0 -ceramide as compared with controls ( Fig. 3A and (Table I ). In addition, the level of C 18:0 -ceramide in the serum of HNSCC patients were similar to that of their noncancerous head and neck tissues (the average value of C 18:0 -ceramide in the serum of these patients was ϳ10.5 pmol/500 g protein), suggesting that the amount of this ceramide in the tumor site, and not in the whole blood/serum, may be important for its regulatory roles in the pathogenesis/progression of the HNSCC.
Interestingly, in nonsquamous tissues (n ϭ 10), a selective decrease in the levels of C 18 -ceramide was not detected. Instead, lower levels of C 16 -and C 18 -ceramides (lower in 6 of 10 patients; p Ͻ 0.05), were observed in the tumor tissues as compared with their adjacent noncancerous tissues (Fig. 3, B and C, respectively, and Table II) . Similar results were also observed in nonsquamous cell lung carcinomas, in which significantly reduced levels of C 16 -, C 18 -, and C 24 -ceramides were detected in the majority of the tumors (ϳ80%) as compared with their adjacent normal lung tissues (n ϭ 10, p Ͻ 0.001, data not shown).
Taken together, these results suggest an important and novel role for C 18 -ceramide and LAG1 in the pathogenesis/ progression of the HNSCC, whereas in nonsquamous tumors (head and neck, and lung), decreased levels of major ceramides such as C 16 -, C 18 -, and C 24 -ceramides appear to be important.
Analysis of the Role of C 18:0 -ceramide by Overexpression of the mLAG1/mUOG1 cDNA in the Regulation of Cell Growth in UM-SCC-22A Cells-Decreased levels of C 18:0 -ceramide in the majority of the HNSCC tumor tissues compared with their adjacent noncancerous tissues suggested the hypothesis that although altered levels of C 18 -ceramide might play important roles in the pathogenesis/progression of HNSCC, its increased generation/accumulation might regulate the growth of HNSCC cells. To test this hypothesis, mLAG1/mUOG1 was overexpressed in the human HNSCC cell line UM-SCC-22A (SCC of the hypopharynx) as described under "Experimental Procedures." Overexpression of mLAG1/mUOG1 was confirmed by Q-PCR (Fig. 4A) . This resulted in an increase selectively in the levels of C 18 -ceramide from ϳ6 to 11.5 pmol/0.5 mg protein (Fig. 4B) , which are similar to the levels detected in normal head and neck tissues ( Fig. 2A) . Interestingly, the levels of other major ceramides such as C 14 -, C 24 -, and dihydro-C 16 -ceramides (Fig. 4C, left panel) and C 16 -ceramide (Fig. 4C, right  panel) were decreased significantly, when compared with vector-transfected controls.
The Effects of mLAG1/mUOG1 on the Regulation of Growth, Telomerase Activity, and Apoptosis-The effects of overexpression of mLAG1/mUOG1 on cell growth were examined using the trypan blue exclusion assay. The results demonstrated that mLAG1/mUOG1 expression caused ϳ82% inhibition of cell growth as compared with controls (Fig. 5A) . Similar results were also obtained using MTT assays, in which overexpression of mLAG1/mUOG1 resulted in ϳ80% decrease in cell growth in these cells (data not shown).
Because ceramide is known to mediate the inhibition of telomerase in various human cancer cells (8, 9) and because telomerase activity has been detected in the majority of HNSCC tumors and not in normal head and neck tissues (12) (13) (14) (15) , the role of C 18 -ceramide in the inhibition of telomerase was examined in UM-SCC-22A cells. The data showed that increased generation of C 18 -ceramide by mLAG1/mUOG1 re- 
sulted in a significant inhibition of telomerase activity (ϳ50%) when compared with controls (Fig. 5B, lanes 2 and 1, respectively) . Interestingly, additional data using Q-PCR indicated that the inhibition of telomerase activity by LAG1/C 18 -ceramide may not be due to decreased mRNA expression of its catalytic human telomerase reverse transcriptase (hTERT) (shown in Fig. 5C ) or human telomerase RNA (hTR) subunits (data not shown), suggesting a post-transcriptional regulation.
In addition, analysis of cell cycle by flow cytometry showed that mLAG1/mUOG1 significantly increased the number of apoptotic cells in the sub-G 0 /G 1 , whereas there were no significant changes in the cell cycle profiles (Fig. 5D ). To further evaluate whether mLAG1/mUOG1/C 18 -ceramide-induced apoptosis involves the mitochondrial death pathway, analysis of mitochondrial potential using JC-1 by flow cytometry was performed as described under "Experimental Procedures." The data showed that mLAG1/mUOG1 expression resulted in a significant loss of mitochondrial membrane potential, as determined by increased accumulation of JC-1 (ϳ39%) as green monomers in the cytoplasm (Fig. 5E) , suggesting a role for LAG1/C 18 -ceramide in mediating the mitochondrial death pathway.
To determine whether the role of increased generation of C 18:0 -ceramide by mLAG1/mUOG1 in the inhibition of growth is cell line-specific, mLAG1/mUOG1 was expressed in another human HNSCC cancer cell line, UM-SCC-1 (squamous cell carcinoma of the floor of the mouth), and the levels of ceramides and its effects on growth were determined using LC/MS and MTT assays, respectively. Expression of mLAG1/mUOG1, confirmed by RT-PCR (Fig. 6A, right panel), resulted in a signifi-FIG. 3 . Analysis of the levels of ceramides in HNSCC and nonsquamous head and neck cancer tissues. Levels of C 18 -ceramide was measured in 15 additional HNSCC tissues (patients 18 -32) that did not have paired normal adjacent tissues and compared with the average levels of C 18 -ceramide in normal tissues of patients 1-17 (A). In addition, the levels of C 16 -and C 18 -ceramides were measured in 10 tumor patients with nonsquamous head and neck carcinomas and compared with that of their paired adjacent normal tissues (B and C, respectively). Statistical analysis of the data was done using Student's t test, and p Ͻ 0.05 was considered significant. The error bars represent the standard deviations, and when not seen, they are smaller than the thickness of the lines on the graphs.
TABLE II The alterations of C-and C 18 -ceramides in nonsquamous head
and neck cancer tumors Ceramide levels in nonsquamous head and neck tumor tissues were measured by LC/MS. The ceramide levels are shown as percentages of change compared with that of their paired normal adjacent tissues. The results are the means of at least two independent measurements, and the standard deviations are shown in parentheses. Statistical analysis was performed using Student's t test, and p Ͻ 0.05 was considered significant. Patients with significantly reduced ceramide are shown in bold type. PC/A, papillary carcinoma/adenoma; PA, pleomorphic adenoma; OS, osteosarcoma; GN, ganglioneuroma; CCC, clear cell carcinoma. Patient Oral cavity (CCC) 38 (4.3) 45 (11) cant increase (ϳ6-fold) in the generation of C 18:0 -ceramide (Fig.  6, A and B) , whereas the levels of other ceramides, especially C 16 -ceramide, were significantly reduced as compared with controls (Fig. 6B, upper and lower panels) . Increased levels of C 18:0 -ceramide in response to mLAG1/mUOG1 overexpression were also accompanied by a significant inhibition of cell growth (ϳ70%) in these cell lines (Fig. 6C) . Thus, these results strongly demonstrate that inhibition of growth by mLAG1/mUOG1 and C 18:0 -ceramide is not cell line-specific but rather can be detected in other human HNSCC cell lines.
DISCUSSION
The results presented in this study demonstrate that decreased levels of C 18:0 -ceramide might play a role in the pathogenesis/progression of the HNSCC; on the other hand, in nonsquamous tissues, this selectivity for C 18 -ceramide was not detected. These results suggest that decreased levels of C 18 -ceramide may impart a growth advantage to cancer cells, whereas increased generation/accumulation of C 18 -ceramide may lead to inhibition of growth of HNSCC cells. This was further supported by the data showing that increased generation of C 18:0 -ceramide via overexpression of mLAG1/mUOG1 results in the inhibition of growth, which involves the modulation of telomerase activity and induction of apoptosis in HNSCC cells. Taken together, these results provide evidence for the role of LAG1 and C 18 -ceramide in the regulation of telomerase and apoptosis in HNSCC cells.
The anti-proliferative roles of endogenous ceramide have been demonstrated in various human cancer cells previously (reviewed in Ref. 7) . A recent study demonstrated that the total ceramide levels are inversely correlated with malignant progression and poor prognosis of astrocytomas (24) . The results from the present study support these conclusions, and they further provide additional information that the levels of specific ceramide species, such as C 18 -ceramide, and not total ceramide levels might also be important in the pathogenesis and regulation of cell growth in some carcinomas such as HNSCC. Therefore, the identification of immediate downstream targets of C 18 -ceramide, which are involved in the inhibition of cell growth in HNSCC cells, is extremely important and of great interest in our laboratory. In fact, the present study shows that overexpression of mLAG1/mUOG1 results in the inhibition of telomerase activity, which has been shown to be elevated in the majority of HNSCC tumor tissues and not in the normal tissues (12) (13) (14) (15) . Thus, these results support that telomerase is one of the cancer-specific targets of endogenous ceramide. Interestingly, inhibition of telomerase in response to C 6 -ceramide or daunorubicin was linked to the generation of endogenous C 16 -and C 24 -ceramides in the A549 human lung adenocarcinoma cells (8) . This inhibition, however, was mainly due to decreased mRNA expression of human telomerase reverse transcriptase and correlated with cell cycle arrest but not apoptosis. However, in HNSCC cells, the inhibition of telomerase activity by LAG1/C 18 -ceramide pathway appears to be at the post-transcriptional level and correlates with apoptosis. Thus, these data suggest that specific ceramides might have distinct functions in the regulation of telomerase and apoptosis, and these functions might be cell type-or tissue-specific.
LAG1 was discovered in yeast, and it has been shown that deletion of LAG1 extends the life span in yeast (17, 25, 26) . The mammalian homologues of yeast LAG1 were later identified in mice, called mammalian upstream of growth and differentiation 1, mUOG1 (19) , and in human called human LAG1 (also referred to as LASS1, human longevity assurance homologue 1 of yeast LAG1) (17, 25) . The mUOG1 and human LAG1 have been shown to have Ͼ80% amino acid homology (20) . Further studies showed that the biological activities of LAG member genes encode essential components of acyl-CoA-dependent (dihydro)-ceramide synthase (18) . Interestingly, mUOG1 has been shown to be involved in the synthesis of C 18 (stearic acid) containing sphingolipids, including C 18:0 -ceramide (19) . However, the role for these LAG member proteins in the regulation of cell growth in mammals has not been shown previously. Therefore, our results presented here demonstrate that LAG1/ C 18 -ceramide is involved in the regulation of cell growth in UM-SCC-22A and UM-SCC-1 cells.
Interestingly, our data demonstrated that the levels of C 16 -ceramide is significantly up-regulated in HNSCC tumors as compared with their normal adjacent tissues. In parallel with these findings, the level of C 16 -ceramide is greatly reduced upon mLAG1/mUOG1 overexpression and increased generation of C 18 -ceramide in HNSCC cells (see Figs. 4 and 6) . These results are surprising, because the role for increased C 16 -ceramide in apoptosis upon induction by IgM via de novo pathway in Jurkat cells, or in cell cycle arrest and the inhibition of telomerase activity in the A549 nonsquamous lung cancer cells, has been demonstrated previously (10, 27) . Therefore, determining the possible relationship, if any, between increased levels of C 16 -ceramide in HNSCC tumors and its decreased levels in response to mLAG1/mUOG1 expression in HNSCC cell lines is important and needs to be further explored. In light of this, specific downstream targets and subcellular localization/compartmentalization of these ceramides (C 16 -and C 18 -FIG. 5. Effects of mLAG1/mUOG1 on the regulation of growth, telomerase activity, and apoptosis. The effects of increased C 18 -ceramide via overexpression of mLAG1/mUOG1 after transient transfections for 48 h on cell growth was detected by trypan blue studies (A). Telomerase activity was determined by the TRAP assay as described under "Experimental Procedures" (B). The 36-bp nontelomerase product was used as an internal control (IC) in the TRAP assay kit. The quantification of telomerase activity was done as described by the manufacturer using the Quantity One (Bio-Rad) software. The mRNA levels of hTERT (C) was measured by Q-PCR, and the levels were normalized to that of ␤-actin. Cell cycle profiles and apoptotic cell populations (sub-G 0 /G1) were detected by flow cytometry as described under "Experimental Procedures" (D). Mitochondrial membrane potential was measured using the JC-1 kit by flow cytometry (E) as described under "Experimental Procedures." The results shown are representative of at least two independent experiments. The error bars represent the standard deviations. ceramides) might be involved in their distinct functions for the regulation of growth or apoptosis in various different types of cancer cells, and this is of great interest in our laboratories.
It is also known that increased ceramide generation in response to various stress stimuli including radiation and chemotherapeutic agents can result in the inhibition of growth of various cancer cells (28 -30) . Treatment of the Tu138 human head and neck squamous cell carcinoma cells with paclitaxel and C 6 -ceramide in combination synergistically inhibited cell growth (31), demonstrating a role for ceramide in the treatment of head and neck cancer cells in vitro. However, the clinical relevance of ceramide in HNSCC is still unknown. The results also indicate that the use of LC/MS (9, 32, 33) , which can identify the levels of different ceramide species in a given sample, is a powerful tool to discover the roles for specific ceramide species (with different fatty acid chain length) in the pathogenesis of various carcinomas including HNSCC. In fact, metabolomic profiling of sphingolipids in human glioma cell lines have been performed previously (34) . The results have shown that different glioma cell lines had differences in the amounts and types of sphingolipids, and the fatty acyl chain distributions of sphingolipids were also different among these cell lines (34) . It is also interesting that our results specifically showed decreased levels of C 18 -ceramide selectively in the squamous cell carcinoma of the head and neck tissues, whereas lower levels of C 16 -and C 18 -ceramides were detected in nonsquamous head and neck tumor tissues. The association of lower C 18 -ceramides, if any, with prognosis and/or survival in these patients with HNSCC could not be examined because of the high grades of the tumors and the lack of follow up information about the patients for a longer period of time. The clinical importance of C 18 -ceramide in overall survival and prognosis in HNSCC needs to be determined in studies with a larger cohort of patients.
